NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
RINVOQ (upadacitinib) by AbbVie is janus kinase inhibitors [moa]. First approved in 2019.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RINVOQ (upadacitinib) is an oral Janus Kinase inhibitor approved in 2019 for inflammatory conditions including rheumatoid arthritis and atopic dermatitis. It selectively inhibits JAK1, modulating immune signaling pathways to reduce inflammation and disease progression. The extended-release tablet formulation enables once-daily dosing for improved patient adherence.
$0.976BPart D
Peak11.3 years to LOEProduct is at peak commercial maturity with substantial Medicare utilization; brand and commercial teams remain fully resourced for market expansion and indication growth.
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Started Jan 2027
154 enrolled
Non-Segmental Vitiligo
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Started Oct 2026
50 enrolled
UC - Ulcerative Colitis
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Started Oct 2026
30 enrolled
JAK1 GOFSTAT1 GOFSTAT3 GOF+2 more
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Started Sep 2026
52 enrolled
EoEEosinophilic EsophagitisEosinophilic Esophagitis (EoE)
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)
Started Sep 2026
900 enrolled
Atopic Dermatitis
Worked on RINVOQ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.